TGen/Virginia G. Piper Cancer Center publish results of new drug for pancreatic cancer patients

Results lead to Scottsdale oncologists heading a large phase III study being conducted worldwide

2011-10-06

(Press-News.org) SCOTTSDALE, Ariz. -- Patients at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare were the first in the nation to participate in a clinical trial to determine the safety, tolerability and effectiveness for usage of a new drug combination consisting of a standard drug called gemcitabine and a drug called nab-paclitaxel for patients with advanced pancreatic cancer.

The results of this study, headed by renowned pancreatic cancer expert Dr. Daniel Von Hoff, were published online Oct. 3, 2011, in the prestigious Journal of Clinical Oncology.

Nab-paclitaxel (Abraxane), an albumin-bound formulation of paclitaxel, is a drug manufactured by Abraxis BioScience a wholly-owned subsidiary of Celgene and is approved for the treatment of patients with advanced breast cancer. The use of this agent in patients with pancreatic cancer is investigational.

Virginia G. Piper Cancer Center Clinical Trials is a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) to rapidly bring new discoveries in the laboratory to patients.

"This is a great example of rapid bench to bedside development," said Dr. Von Hoff, TGen's Physician-In-Chief and Chief Scientific Officer for the Scottsdale Healthcare Research Institute.

Scientists at TGen and the International Genomics Consortium, in collaboration with Abraxis scientists, found that in pancreatic cancer an albumin-binding protein called SPARC was present at high levels in cells within the pancreatic tumor microenvironment. It was hypothesized that the albumin formulation of nab-paclitaxel may be taken up by tumor cells with high SPARC expression. Based on these findings, Dr. Von Hoff -- joined by colleagues from Johns Hopkins University Hospital, Baltimore; University of Alabama, Birmingham; and South Texas Oncology-Hematology, San Antonio -- conducted a clinical trial in patients with advanced pancreatic cancer.

The results of this pilot study in which 67 patients were treated showed impressive results. Following completion of a safety and dose finding phase, 44 patients were treated in the phase II group. About half the patients showed reductions in tumor size measured by CT scans, and about 50 percent lived at least a year.

"Compared to the average survival of 6 months seen typically in this group of patients, this is very encouraging," said Dr. Ramesh Ramanathan, medical director, Virginia G. Piper Cancer Center Clinical Trials. He added that the results of this study need to be confirmed. A large worldwide study of 842 patients comparing the standard treatment of gemcitabine to the new regimen of gemcitabine and nab paclitaxel is underway, led by Dr. Von Hoff and Dr. Ramanathan.

According to Dr. Ron Korn, the lead radiologist and a co-author on this paper, the study also provided important information on the role of PET scans. "If we can find early in the course of treatment if a patient will respond to treatment or not, then we can change course quickly, this study showed that patients who had a decrease in intensity of 'hot spots' on a PET scan after 6 weeks of treatment were more likely to have a good outcome." Dr. Korn added that this approach is being further investigated in clinical trials with targeted agents in collaboration with the Virginia G. Piper Cancer Center.

Individuals seeking information about eligibility to participate in clinical trials at the Virginia G. Piper Cancer Center at Scottsdale Healthcare may contact the cancer care coordinator at 480-323-1339; toll free at 1-877-273-3713 or via email at clinicaltrials@shc.org.

### About the Virginia G. Piper Cancer Center at Scottsdale Healthcare The Virginia G. Piper Cancer Center at Scottsdale Healthcare in Scottsdale, Ariz. offers comprehensive cancer treatment and research through Phase I clinical trials, diagnosis, treatment, prevention and support services in collaboration with leading scientific researchers and community oncologists. Scottsdale Healthcare is the nonprofit parent organization of the Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale Healthcare Research Institute, Scottsdale Healthcare Osborn Medical Center, Scottsdale Healthcare Shea Medical Center and Scottsdale Healthcare Thompson Peak Hospital. For more information, visit http://www.shc.org.

Press Contact:
Keith Jones
Public Relations Director
Virginia G. Piper Cancer Center
480-323-1383
kjones@shc.org

About TGen The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, visit: http://www.tgen.org.

Press Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
syozwiak@tgen.org

ELSE PRESS RELEASES FROM THIS DATE:

New tool helps identify prostate cancer patients with highest risk of death

2011-10-06

Fox Chase Researchers Develop a New Tool That Helps Identify Prostate Cancer Patients with the Highest Risk of Death MIAMA BEACH, FL (October 4, 2011)––After a prostate cancer patient receives radiation treatment, his doctor carefully monitors the amount of prostate-specific antigen, or PSA, in his blood. An increase in PSA, called biochemical failure, is the first detectable sign of the cancer's return to the prostate. Fox Chase Cancer Center researcher have found that the time between the last radiation treatment and biochemical failure can accurately predict a patient's ...

Fox Chase Gleason scores better predict prostate cancer's recurrence after radiation

2011-10-06

MIAMA BEACH, FL (October 4, 2011)––In a new study led by Fox Chase Cancer Center radiation oncologist Natasha Townsend, M.D., researchers have found that Gleason scores determined by pathologists at Fox Chase Cancer Center more accurately predict the risk of recurrence than Gleason scores from referring institutions. She presented the new research at the 53rd Annual Meeting of the American Society for Radiation Oncology on Monday, October 3. When a man is diagnosed with prostate cancer, his tumor is assigned a Gleason score – a number between 2 and 10 indicating the ...

Study shows looking for job on Internet reduces unemployment time

2011-10-06

DENVER (Oct. 5, 2011) – A new study shows that using the Internet to look for a job reduces the time spent unemployed by an average of 25 percent. The discovery directly contradicts a 2004 study showing that using the Internet actually prolonged unemployment. "In 2004 the researchers came up with two scenarios for their findings – the Internet was not an effective tool or that people who looked on-line for jobs were not as qualified," said Hani Mansour, Ph.D., assistant professor of economics at the University of Colorado Denver who conducted the new study with Peter ...

Hundreds of undiscovered artifacts found at Gallipoli

2011-10-06

More than 100 artefacts from the First World War have been uncovered in an archaeological fieldwork survey on the Gallipoli battlefield, leading to some interesting theories about life on the frontline according to University of Melbourne survey archaeologist Professor Antonio Sagona. The discoveries were made as part of a second season of fieldwork undertaken as part of the Joint Historical and Archaeological Survey – the only systematic survey of the battlefields of Gallipoli since the First World War. The survey covered the northern frontline areas on the Turkish ...

A new leaf turns in carbon science

2011-10-06

A new insight into global photosynthesis, the chemical process governing how ocean and land plants absorb and release carbon dioxide, has been revealed in research that will assist scientists to more accurately assess future climate change. In a paper published today in Nature, a team of US, Dutch and Australian scientists have estimated that the global rate of photosynthesis, the chemical process governing the way ocean and land plants absorb and release CO2, occurs 25% faster than previously thought. From analysing more than 30 years of data collected by Scripps Institution ...

Practical play: Interactive video games appear valuable for ICU patients

2011-10-06

Interactive video games, already known to improve motor function in recovering stroke patients, appear to safely enhance physical therapy for patients in intensive care units (ICU), new research from Johns Hopkins suggests. In a report published online in the Journal of Critical Care, researchers studied the safety and feasibility of using video games to complement regular physical therapy in the ICU. "Patients admitted to our medical intensive care unit are very sick and, despite early physical therapy, still experience problems with muscle weakness, balance ...

Survey reveals reasons doctors avoid online error-reporting tools

2011-10-06

"Too busy," and "too complicated." These are the typical excuses one might expect when medical professionals are asked why they fail to use online error-reporting systems designed to improve patient safety and the quality of care. But, Johns Hopkins investigators found instead that the most common reason among radiation oncologists was fear of getting into trouble and embarrassment. Investigators e-mailed an anonymous survey to physicians, nurses, radiation physicists and other radiation specialists at Johns Hopkins, North Shore- Long Island Jewish Health System in New ...

Blood tests may hold clues to pace of Alzheimer's disease progression

2011-10-06

A team of scientists, led by Johns Hopkins researchers, say they may have found a way to predict how quickly patients with Alzheimer's disease (AD) will lose cognitive function by looking at ratios of two fatty compounds in their blood. The finding, they say, could provide useful information to families and caregivers, and might also suggest treatment targets for this heartbreaking and incurable neurodegenerative disorder. Past research has shown that cognitive function declines at different rates in AD patients, with roughly one-third not declining at all in five years, ...

Women with PCOS have family heart disease link

2011-10-06

A new study from the University of Adelaide shows the parents of women with polycystic ovary syndrome (PCOS) are more likely to have some form of cardiovascular disease. PCOS is a hormonal disorder affecting about 10% of women of reproductive age. It is one of the most common endocrine disorders in women and a leading cause of infertility. The study shows mothers of women with PCOS are more likely to have any form of cardiovascular disease, and almost twice as likely to have high blood pressure, than mothers of other women. Fathers of women with PCOS are more than ...

Think you’re in poor health? It could increase your odds of dementia

2011-10-06

ST. PAUL, Minn. – People who rate their health as poor or fair appear to be significantly more likely to develop dementia later in life, according to a study published in the October 5, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology. "Having people rate their own health may be a simple tool for doctors to determine a person's risk of dementia, especially for people with no symptoms or memory problems," said study author Christophe Tzourio, MD, PhD, director of the Inserm unit 708 Neuroepidemiology at the University of Bordeaux ...

TGen/Virginia G. Piper Cancer Center publish results of new drug for pancreatic cancer patients

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: